WASHINGTON, March 4 (TNSjou) -- Researchers at Harvard Medical School and Dana-Farber Cancer Institute have developed a virus-based therapy that successfully recruits immune cells to combat aggressive brain tumors. Results from a phase 1 clinical trial involving 41 patients with recurrent glioblastoma indicate that a single injection of a genetically modified oncolytic virus can penetrate and destroy cancer cells while inducing a protective immune response.

Study co-senior author Ka . . .

Click here for more information about our products